Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Intern Med ; 61(13): 1947-1952, 2022.
Artículo en Inglés | MEDLINE | ID: mdl-35781270

RESUMEN

Objective We evaluated the performance of the revised classification criteria for assessing different systemic autoimmune rheumatic diseases and their overlap syndromes. Methods A total of 652 patients with or highly suspected of having systemic lupus erythematosus (SLE), systemic sclerosis (SSc), polymyositis (PM)/dermatomyositis (DM) or rheumatoid arthritis (RA) were included in this study. The 1997 revised American College of Rheumatology (ACR) and the 2019 European League Against Rheumatism (EULAR)/ACR criteria for SLE, the 1980 ACR and the 2013 ACR/EULAR criteria for SSc, the criteria by Bohan and Peter and the 2017 EULAR/ACR criteria for PM/DM, and the 1987 revised ACR and 2011 ACR/EULAR criteria for RA were used for disease classification. Results The old and new criteria and a clinical diagnosis were used to respectively classify 103, 106 and 105 SLE patients; 35, 47 and 58 SSc patients; 18, 23 and 33 PM/DM patients; and 297, 389 and 468 RA patients. Sensitivity increased from 82.9% to 92.4% in SLE, from 56.9% to 79.3% in SSc, from 54.5% to 66.7% in PM/DM, and from 62.6% to 80.8% in RA. SLE-SSc was the predominant type of clinical overlap syndrome, while SLE-RA was the most classifiable. Conclusion The revised classification criteria for all the diseases showed an improved sensitivity, and SLE-overlap syndrome was predominant, regardless of the criteria sets.


Asunto(s)
Artritis Reumatoide , Enfermedades Autoinmunes , Enfermedades del Tejido Conjuntivo , Dermatomiositis , Lupus Eritematoso Sistémico , Enfermedades Reumáticas , Esclerodermia Sistémica , Artritis Reumatoide/diagnóstico , Enfermedades Autoinmunes/diagnóstico , Dermatomiositis/diagnóstico , Humanos , Lupus Eritematoso Sistémico/diagnóstico , Enfermedades Reumáticas/diagnóstico , Esclerodermia Sistémica/diagnóstico , Síndrome
2.
Arthritis Care Res (Hoboken) ; 73(2): 173-179, 2021 02.
Artículo en Inglés | MEDLINE | ID: mdl-31651103

RESUMEN

OBJECTIVE: Joint destruction in rheumatoid arthritis (RA) includes both bone and cartilage lesions. Since joint space narrowing (JSN) is not a direct evaluation of cartilage using radiography, we aimed to examine the validity of ultrasound (US) cartilage evaluation using a semiquantitative method in patients with RA. METHODS: We enrolled 103 patients with RA who were in remission or showing low disease activity and 42 healthy subjects. The cartilage thickness of the bilateral metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints of the second to fifth fingers was measured by US, and the recorded images were scored semiquantitatively using a scale of 0-2. In addition, the JSN of the corresponding joints was scored using a hand radiograph. The relationships between total cartilage thickness, its semiquantitative score, and JSN score were assessed using Spearman's rank correlation coefficients. RESULTS: Total cartilage thickness was significantly thinner in patients with RA compared to healthy subjects for both the MCP and PIP joints (both P < 0.001). The semiquantitative sum of 16 joints ranged from 2 to 26 (median 8) in patients with RA, which was significantly greater than the 0-11 (median 4) in healthy subjects (P < 0.001). In patients with RA, the semiquantitative score showed a significant negative correlation with cartilage thickness (ρ = -0.64, P < 0.001) and a significant positive correlation with JSN score (ρ = 0.66, P < 0.001). Furthermore, these scores showed a significant correlation with RA disease duration. CONCLUSION: A simplified and direct evaluation of finger joint cartilage damage by semiquantitative US score is valid and useful for patients with RA.


Asunto(s)
Artritis Reumatoide/diagnóstico por imagen , Cartílago Articular/diagnóstico por imagen , Articulaciones de los Dedos/diagnóstico por imagen , Articulación Metacarpofalángica/diagnóstico por imagen , Ultrasonografía , Anciano , Estudios de Casos y Controles , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Reproducibilidad de los Resultados , Índice de Severidad de la Enfermedad
3.
Mod Rheumatol ; 30(3): 558-563, 2020 May.
Artículo en Inglés | MEDLINE | ID: mdl-31084231

RESUMEN

Objectives: To examine the development and exacerbation of pulmonary nontuberculous mycobacterial (NTM) infection in patients with systemic autoimmune rheumatic diseases (SARD).Methods: We conducted a case-control study. Seventeen of 7013 patients with SARD fulfilling the criteria for pulmonary NTM infection were enrolled in the NTM group. The control group was matched for age, sex, and SARD at a ratio of 2:1.Results: Eight patients with rheumatoid arthritis, four with systemic vasculitis, three with Sjögren's syndrome, and one each with dermatomyositis and systemic lupus erythematosus were included in the NTM group. Mycobacterium avium was detected in 12 (71%) patients, M. chelonae in 2, and M. intracellulare, M. abscessus, and M. kansasii in 1 patient each. Preexisting lung disease was more common in the NTM group than in the control group (88% versus 38%, p = .0009), particularly bronchiectasis (65% versus 29%, p = .033). The body mass index and serum albumin level were significantly lower in the NTM group than in the control group. Six patients (35%) experienced NTM exacerbation during observation. Clinical immune status at the time of NTM diagnosis, as indicated by the peripheral blood leukocyte/lymphocyte count and serum immunoglobulin G level, was unremarkable and comparable between patients with and without exacerbation, as were the treatments for SARD.Conclusions: In patients with SARD, pulmonary NTM infection may develop and exacerbate without clinically apparent immunosuppression.


Asunto(s)
Enfermedades Autoinmunes/complicaciones , Inmunosupresores/efectos adversos , Infecciones por Mycobacterium no Tuberculosas/epidemiología , Infecciones Oportunistas/epidemiología , Neumonía/epidemiología , Enfermedades Reumáticas/complicaciones , Adulto , Anciano , Enfermedades Autoinmunes/tratamiento farmacológico , Enfermedades Autoinmunes/microbiología , Femenino , Humanos , Inmunosupresores/uso terapéutico , Masculino , Persona de Mediana Edad , Infecciones por Mycobacterium no Tuberculosas/etiología , Infecciones Oportunistas/etiología , Neumonía/etiología , Enfermedades Reumáticas/tratamiento farmacológico , Enfermedades Reumáticas/microbiología
5.
Semin Arthritis Rheum ; 47(3): 310-314, 2017 12.
Artículo en Inglés | MEDLINE | ID: mdl-28532573

RESUMEN

OBJECTIVE: The aim of the study is to assess the factors associated with clinical remission of patients with rheumatoid arthritis (RA) in daily clinical practice. METHODS: This analysis was based on the data of 304 RA patients in our center between May 2014 and March 2015. The following information was included: tender, swollen, and symptomatic joint counts, patient's and physician's global assessments, functional disability, laboratory and radiographic data, and RA treatments received. RESULTS: The patients were predominantly female (77.6%), with a median age of 71 years and a median disease duration of 5.8 years. Clinical remission rate, determined using the simplified disease activity index (SDAI), was 49.7%. Patient's and physician's global assessments (/10cm) showed a higher score among patients who did not achieve SDAI remission than among those who did (median: 3.2 versus 0.3, p < 0.0001; and median: 1.8 versus 0.3, p < 0.0001, respectively). The contribution of serum C-reactive protein values (mg/dL) to SDAI was limited (median: 0.19 versus 0.06; p < 0.0001), as well as tender or swollen joint counts (median = 0 or 1). On multivariate analysis of factors not directly related to the disease activity, age was an independent risk factor for non-remission, and global assessment scores by patients and physicians showed an age-dependent increase, while counts of tender, swollen and symptomatic joints were comparable among elderly and non-elderly patients. CONCLUSION: Global assessment of disease activity was age-dependent and independent of joint counts, and it provides a critical determinant of clinical non-remission.


Asunto(s)
Factores de Edad , Artritis Reumatoide/fisiopatología , Autoevaluación Diagnóstica , Evaluación de la Discapacidad , Articulaciones/fisiopatología , Examen Físico/métodos , Anciano , Antirreumáticos/uso terapéutico , Artritis Reumatoide/diagnóstico por imagen , Artritis Reumatoide/tratamiento farmacológico , Proteína C-Reactiva/análisis , Estudios de Casos y Controles , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Dimensión del Dolor , Radiografía , Inducción de Remisión , Estudios Retrospectivos , Índice de Severidad de la Enfermedad
6.
Arthritis Care Res (Hoboken) ; 69(6): 801-806, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-27564121

RESUMEN

OBJECTIVE: Ultrasonography has been prevalently used as a valid and objective modality for joint examination in patients with rheumatoid arthritis (RA). This study aimed to examine and compare the concordance between ultrasound, clinical assessment, and patient-reported assessment of joint synovitis in RA. METHODS: Fifty patients with RA (84% female, median age 69 years, median disease duration 31 months, and median Disease Activity Score in 28 joints 3.8) completed the self-evaluation of joint symptoms, including pain and considerable stiffness in the (proximal) interphalangeal, metacarpophalangeal, wrist, elbow, shoulder, knee, and ankle joints. These joints were also examined by a physician in order to assess the presence of tenderness or swelling; the presence of imaging synovitis was assessed by ultrasonography. RESULTS: In a total of 1,492 evaluated joints, symptoms (pain and stiffness), tenderness, and swelling were noted in 288 (19.3%), 182 (12.2%), and 220 (14.7%) joints, respectively, while ultrasound indicated synovitis in 317 (21.2%) joints. Overall concordance with ultrasound findings was lowest for joint tenderness (κ = 0.30), followed by symptoms (κ = 0.39), and by swelling (κ = 0.43), irrespective of the evaluated joint, except for the elbow. Moreover, the percentages of inflamed joints detected only on the basis of symptoms, tenderness, or swelling were 18.6%, 2.2%, and 8.5%, respectively, of all joints with signs of synovitis on ultrasonography. CONCLUSION: Joint swelling showed the best concordance with ultrasonography, followed by patient-reported joint symptoms, and joint tenderness. Joint symptoms, rather than tenderness evaluation, may be a better clinical indicator of synovitis in RA patients.


Asunto(s)
Artritis Reumatoide/diagnóstico por imagen , Autoevaluación Diagnóstica , Rol del Médico , Sinovitis/diagnóstico por imagen , Ultrasonografía Doppler/normas , Adulto , Anciano , Anciano de 80 o más Años , Artritis Reumatoide/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Método Simple Ciego , Sinovitis/epidemiología
10.
Exp Anim ; 54(2): 155-61, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15897625

RESUMEN

The common bile duct-ligated (CBDL) rat, which is widely used as a model of human cirrhosis, rapidly develops secondary biliary cirrhosis (SBC) within 4 weeks. The CBDL rat shows poor viability, however, a detailed examination of the causes of its death has not been made. In this study, we investigated the outcome of bile duct ligation in detail and attempted to extend the life span of this model by feeding the animals a diet supplemented with nutrients. Survival rate, blood chemistry, blood cell counts, plasma levels of K vitamins and liver histology were compared among CBDL rats fed a standard diet and an enriched diet. Sham-operated rats were used as a control. Six out of 18 CBDL rats fed the standard diet died within 32 days of operation. The cause of death was massive internal hemorrhage in various organs or body cavities. All CBDL rats fed the enriched diet survived more than 31 days, but the viability of CBDL rats was not significant between those fed the standard diet and the enriched diet. The degree of anemia correlated significantly with the prolongation of prothrombin time. Plasma vitamin K1 levels in CBDL rats were significantly lower than those in sham-operated rats, but vitamin K2 levels were similar. We suggest that massive hemorrhage, which was the direct cause of death, is caused by the impairment of hemostasis resulting from vitamin K deficiency. The enriched diet with vitamin K nutritional supplements seemed to contribute to the prolongation of the life span of CBDL rats.


Asunto(s)
Cirrosis Hepática Biliar/sangre , Cirrosis Hepática Biliar/etiología , Vitamina K 1/sangre , Animales , Modelos Animales de Enfermedad , Hemorragia/dietoterapia , Hemorragia/etiología , Hemostasis , Ligadura/efectos adversos , Cirrosis Hepática Biliar/dietoterapia , Cirrosis Hepática Biliar/mortalidad , Masculino , Ratas , Ratas Sprague-Dawley , Tasa de Supervivencia , Vitamina K/administración & dosificación , Vitamina K 2/sangre , Deficiencia de Vitamina K/complicaciones , Deficiencia de Vitamina K/fisiopatología
11.
Clin Neurol Neurosurg ; 106(2): 139-41, 2004 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15003307

RESUMEN

Osteoporosis is an adverse effect of prednisolone therapy, although no study has been conducted on myasthenia gravis patients receiving high-dose prednisolone. We measured bone density in 36 patients (26 females and 10 males) who had undergone long-term prednisolone administration, and found a decrease in bone density in 31% of female patients and osteoporosis in only 11.5% (three cases). This frequency is lower than the presumptive rate of the general population in Japan (22.6%). No osteoporosis was detected in male patients. In conclusion, prednisolone-treated patients with myasthenia gravis have an acceptable risk of bone loss if prophylactic medication is administered.


Asunto(s)
Densidad Ósea/efectos de los fármacos , Inmunosupresores/efectos adversos , Miastenia Gravis/tratamiento farmacológico , Prednisolona/efectos adversos , Absorciometría de Fotón , Adulto , Anciano , Anciano de 80 o más Años , Autoanticuerpos/sangre , Estudios Transversales , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Inmunosupresores/administración & dosificación , Japón/epidemiología , Cuidados a Largo Plazo , Masculino , Persona de Mediana Edad , Miastenia Gravis/inmunología , Osteoporosis/inducido químicamente , Osteoporosis/diagnóstico , Osteoporosis/epidemiología , Prednisolona/administración & dosificación , Receptores Colinérgicos/inmunología , Riesgo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...